Research

Whole genome sequencing identifies recurrent mutations in hepatocellular carcinoma

    • 1 Pfizer Oncology;
    • 2 BGI-Shenzhen;
    • 3 Eli Lilly and Company;
    • 4 Merck Research Laboratories;
    • 5 University of Hong Kong;
    • 6 National University of Singapore
Published June 20, 2013. https://doi.org/10.1101/gr.154492.113
Download PDF Cite Article Permissions Share
cover of Genome Research Vol 36 Issue 6
Current Issue:

Abstract

Hepatocellular carcinoma (HCC) is one of the most deadly cancers worldwide and has no effective treatment, yet the molecular basis of hepatocarcinogenesis remains largely unknown. Here we report findings from a whole genome sequencing (WGS) study of 88 matched HCC tumor/normal pairs, 81 of which are HBV positive, seeking to identify genetically altered genes and pathways implicated in HBV-associated HCC. We find beta catenin to be the most frequently mutated oncogene (15.9%) and TP53 the most frequently mutated tumor suppressor (35.2%). The Wnt/beta catenin and JAK/STAT pathways, altered in 62.5% and 45.5% of cases respectively, are likely to act as two major oncogenic drivers in HCC. This study also identifies several prevalent and potentially actionable mutations including activating mutations of Janus Kinase 1 (JAK1) in 9.1% of patients and provides a path towards therapeutic intervention of the disease.

Loading
Loading
Loading
Back to top